• Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • About
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Advertise
PharmaLive
  • Marketing & Advertising
  • R&D
  • Therapeutics
  • Resources
  • Manny Awards
  • Events
  • Issue Archives
  • Subscribe
  • Search
  • Menu

Provention Bio and Johnson & Johnson Ink Deal

Anti-colony-stimulating factor 1 receptor (CSF1R) antibodies, Anti-Toll-Like Receptor 3 (TLR3) monoclonal antibody, Business, Crohn's Disease, Deals, Immune-Mediated Diseases, Influenza, Irritable Bowel Syndrome, Ulcerative Colitis (UC), Vaccines, Viral Diseases

Provention Bio agreed to in-license two clinical-stage assets for immune-mediated diseases from Janssen Pharmaceutica and Janssen Sciences Ireland.

Read more
September 21, 2017/by BioSpace
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2017-09-21 05:59:102017-09-21 13:34:04Provention Bio and Johnson & Johnson Ink Deal
Recent
  • 30-50 Million J&J Vaccine Doses Found Idle in Baltimore...October 28, 2021 - 12:11 pm
  • Novartis Under New DOJ Scrutiny Over Potential Kickback...October 28, 2021 - 11:52 am
  • Merck sees up to $7 billion in sales of COVID-19 drug through...October 28, 2021 - 10:56 am
  • WHO, partners seek $23.4 billion for new COVID-19 war c...October 28, 2021 - 10:25 am
Popular
  • 30-50 Million J&J Vaccine Doses Found Idle in Baltimore...October 28, 2021 - 12:11 pm
  • M&A, Partnerships And CollaborationsJanuary 1, 2011 - 1:48 pm
  • OTC Review And OutlookMarch 9, 2011 - 4:17 pm
  • Global Contract Manufacturing Companies: Pharmaceutical...November 11, 2011 - 3:31 pm
Tags
Abbott appointments biotech cancer Central Nervous System clinical trials Conference Congress CRM depression digital marketing Drugs in Development earnings featured first quarter gene sequencing genomes HCB Health healthcare advertising agencies Infectious Disease Intouch Solutions KOLs legislation multichannel marketing Neurodegenerative Diseases Omnicom Oncology Pain and Inflammation pharmaceutical marketing pharmaceutical promotion pharmceutical promotion Promotions Publicis Quintiles rare disease recruitment Sales & Marketing Shire social media stroke Studies Synthetic Biologics talent Veeva Veeva Systems
© Copyright - PharmaLive and Outcomes LLC | Designed by Joe Lumi LLC
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
Scroll to top